Anebulo Pharmaceuticals (FRA:214) Pre-Tax Income : €-8.64 Mil (TTM As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Anebulo Pharmaceuticals Pre-Tax Income?

Pretax income is the income that a company earns before paying income taxes. Anebulo Pharmaceuticals's pretax income for the three months ended in Mar. 2024 was €-1.52 Mil. Its pretax income for the trailing twelve months (TTM) ended in Mar. 2024 was €-8.64 Mil. Anebulo Pharmaceuticals's pretax margin was %.

Anebulo Pharmaceuticals Pre-Tax Income Historical Data

The historical data trend for Anebulo Pharmaceuticals's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Anebulo Pharmaceuticals Pre-Tax Income Chart

Anebulo Pharmaceuticals Annual Data

Trend

Jun20

Jun21

Jun22

Jun23

Pre-Tax Income

-25.11

-6.46

-10.83

Anebulo Pharmaceuticals Quarterly Data
	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Pre-Tax Income	Get a 7-Day Free Trial										-2.61	-2.30	-2.33	-2.49	-1.52

Competitive Comparison of Anebulo Pharmaceuticals's Pre-Tax Income

For the Biotechnology subindustry, Anebulo Pharmaceuticals's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Anebulo Pharmaceuticals's Pre-Tax Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Anebulo Pharmaceuticals's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where Anebulo Pharmaceuticals's Pre-Tax Income falls into.

Anebulo Pharmaceuticals Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

Anebulo Pharmaceuticals's Pretax Income for the fiscal year that ended in Jun. 2023 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-10.877	+	-0.038	+	0	+	0.085	+	0.00099999999999945
	=	-10.83

Anebulo Pharmaceuticals's Pretax Income for the quarter that ended in Mar. 2024 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-1.531	+	0.002	+	-0.055	+	0.063	+	-0.0010000000000001
	=	-1.52

Pre-Tax Income for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-8.64 Mil.

Anebulo Pharmaceuticals (FRA:214) Pre-Tax Income Explanation

Anebulo Pharmaceuticals's Pretax Margin for the quarter that ended in Mar. 2024 is calculated as

Pretax Margin	=	Pretax Income	/	Revenue
	=	-1.522	/	0
	=	%

Anebulo Pharmaceuticals Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of Anebulo Pharmaceuticals's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Anebulo Pharmaceuticals (FRA:214) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Anebulo Pharmaceuticals Inc (FRA:214) » Definitions » Pre-Tax Income

Comparable Companies

Traded in Other Exchanges

ANEB:USA

Address

1017 Ranch Road 620 South, Suite 107, Lakeway, TX, USA, 78734

Website

https://www.anebulo.com

Anebulo Pharmaceuticals Inc is a clinical-stage biotechnology company. It is developing novel solutions for people suffering from cannabinoid overdose and substance addiction. The product candidate, ANEB-001, is intended to reverse the negative effects of cannabinoid overdose within 1 hour of administration. The signs and symptoms of cannabinoid overdose range from profound sedation to anxiety and panic to psychosis with hallucinations.

Anebulo Pharmaceuticals (FRA:214) Headlines

No Headlines